Repeating platinum/bevacizumab in recurrent or progressive cervical cancer yields marginal survival benefits.
- Citation data:
Gynecologic oncology reports, ISSN: 2352-5789, Vol: 22, Issue: 2, Page: 48-51
- Publication Year:
- Repository URL:
- https://digitalcommons.wustl.edu/open_access_pubs/5877; https://digitalcommons.wustl.edu/open_access_pubs/6493; https://digitalcommons.wustl.edu/open_access_pubs/6205; https://digitalcommons.wustl.edu/open_access_pubs/6494; https://digitalcommons.wustl.edu/open_access_pubs/5810; https://digitalcommons.wustl.edu/open_access_pubs/6313; https://digitalcommons.wustl.edu/open_access_pubs/6254; https://digitalcommons.wustl.edu/open_access_pubs/5910
- 29234709; 28932808; 28529872; 28389382; 28459098; 29326971; 28322738
- 10.1016/j.gore.2017.09.003; 10.1016/j.gore.2017.09.002; 10.1016/j.nicl.2017.05.001; 10.1016/j.neuroimage.2017.04.003; 10.1016/j.gore.2017.04.004; 10.1016/j.gore.2017.12.006; 10.1016/j.ydbio.2017.03.010
- Medicine; Biochemistry, Genetics and Molecular Biology; Neuroscience
- Most Recent Tweet View All Tweets
Our objective was to assess overall survival of cervical cancer patients following prior platinum/bevacizumab chemotherapy, comparing retreatment with platinum/bevacizumab with alternative therapies. A retrospective analysis was performed of women who received platinum/bevacizumab (PB) chemotherapy for cervical cancer at Washington University between July 1, 2005 and December 31, 2015. Wilcoxon rank-sum exact test and Fisher's exact test were used to compare the treatment groups, and Kaplan Meier curves were generated. Cox regression analyses were performed, with treatment free interval and prior therapy response included as covariates. Of 84 patients who received PB chemotherapy, 59 (70%) received no second line chemotherapy, as they did not recur, progressed without further chemotherapy, were lost to follow up, or expired. Of the remaining 25 patients, 9 were retreated with the combination of platinum/bevacizumab (PB), 6 were retreated with a platinum regimen without bevacizumab (P), and 10 were retreated with neither (not-P). The only long-term survivor was in the not-P group and was treated with an immunotherapy agent. Median overall survival of all patients was 7.1 months. There was a marginal difference in survival between women in the PB and not-PB groups (11.8 versus 5.7 months; HR 3.02, 95% CI, 0.98-9.28). There was no difference in survival based on platinum interval (HR 0.81; 95% CI, 0.27-2.45). Outcomes are grim for women retreated after platinum/bevacizumab therapy and are only marginally improved by retreatment with a platinum/bevacizumab regimen. Rather than additional PB therapy, women with cervical cancer who recur after platinum/bevacizumab should consider supportive care or clinical trials.